| Name | Title | Contact Details |
|---|---|---|
Garrie Richardson |
Chief Revenue Officer | Profile |
Marcus Schulz |
Chief Revenue Officer | Profile |
Tim Bush |
Vice President - Strategic Supply Chain Management | Profile |
Bill Yang |
Global Director of Product Management | Profile |
Troy Wichterman |
Chief Financial Officer | Profile |
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.
Anika is a biomedical joint preservation company that leverages proprietary regenerative and restoration therapies to help people feel better faster and remain active. For nearly 30 years and 35 million procedures worldwide, Anika has been passionately advancing quality patient care by enabling people to continue doing what they love. Anika. Your life. In Motion.
We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.
Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.